Introduction

Allograft transplantation is an effective end-point therapy to replace the function of an impaired organ. The main problem associated with allotransplantation is the induction of immune responses that results in acute and chronic graft rejection. To modulate the response of the immune system, transplant recipients generally take high dose immunosuppressant drugs for life. These drugs are associated with serious side effects such as infection with opportunistic pathogens and the development of neoplasia.

Areas covered

We reviewed the obstacles to successful transplantation and PLGA-based strategies to reduce immune-mediated allograft rejection.

Expert opinion

Biomaterial-based approaches using micro- and nanoparticles such as poly (lactic-co-glycolic acid) (PLGA) can be used to achieve controlled release of drugs. This approach decreases the required effective dose of drugs and enables local delivery of these agents to specific tissues and cells, whilst decreasing systemic effects.

中文翻译：

---

PLGA纳米/微粒输送系统在免疫调节和预防同种异体移植排斥中的应用。

介绍

同种异体移植是替代受损器官功能的有效终点疗法。与同种异体移植相关的主要问题是诱导免疫反应，导致急性和慢性移植排斥。为了调节免疫系统的反应，移植受体通常终身服用高剂量的免疫抑制剂药物。这些药物与严重的副作用有关，例如机会性病原体的感染和瘤形成的发展。

覆盖区域

我们回顾了成功移植的障碍和基于PLGA的策略，以减少免疫介导的同种异体移植排斥。

专家意见

使用诸如聚乳酸-乙醇酸共聚物（PLGA）之类的微粒和纳米颗粒的基于生物材料的方法可用于实现药物的受控释放。这种方法降低了所需的药物有效剂量，并使这些药物能够局部递送至特定的组织和细胞，同时降低了全身作用。